{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:55:46Z","timestamp":1791417346313,"version":"4.3.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40120-024-00663-0","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T02:01:45Z","timestamp":1727661705000},"page":"1661-1683","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A Discrete-Choice Experiment Assessing the Patient Preferences and Real-World Experiences of Patients with Migraine in Japan"],"prefix":"10.1007","volume":"13","author":[{"given":"Takao","family":"Takeshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3699-7231","authenticated-orcid":false,"given":"Akira","family":"Yuasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukie Michelle","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis Patrick","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiho","family":"Terasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Abraham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"663_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1080\/03007995.2021.1971179","volume":"37","author":"K Hirata","year":"2021","unstructured":"Hirata K, Ueda K, Komori M, et al. Comprehensive population-based survey of migraine in Japan: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) study. Curr Med Res Opin. 2021;37:1945\u201355.","journal-title":"Curr Med Res Opin"},{"key":"663_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s10194-019-1062-4","volume":"20","author":"T Takeshima","year":"2019","unstructured":"Takeshima T, Wan Q, Zhang Y, et al. Prevalence, burden, and clinical management of migraine in China, Japan, and South Korea: a comprehensive review of the literature. J Headache Pain. 2019;20:111.","journal-title":"J Headache Pain"},{"key":"663_CR3","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/head.14272","volume":"62","author":"T Klan","year":"2022","unstructured":"Klan T, Br\u00e4scher AK, Klein S, et al. Assessing attack-related fear in headache disorders\u2014structure and psychometric properties of the fear of attacks in migraine inventory. Headache. 2022;62:294\u2013305.","journal-title":"Headache"},{"key":"663_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15\u201322.","journal-title":"Cephalalgia"},{"key":"663_CR5","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1526-4610.2004.04004.x","volume":"44","author":"T Takeshima","year":"2004","unstructured":"Takeshima T, Ishizaki K, Fukuhara Y, et al. Population-based door-to-door survey of migraine in Japan: the Daisen study. Headache. 2004;44:8\u201319.","journal-title":"Headache"},{"key":"663_CR6","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/head.14024","volume":"61","author":"R Burch","year":"2021","unstructured":"Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: updated age, sex, and socioeconomic-specific estimates from government health surveys. Headache. 2021;61:60\u20138.","journal-title":"Headache"},{"key":"663_CR7","doi-asserted-by":"publisher","first-page":"5176","DOI":"10.1007\/s12325-022-02289-w","volume":"39","author":"T Takeshima","year":"2022","unstructured":"Takeshima T, Ueda K, Komori M, et al. Potential unmet needs in acute treatment of migraine in Japan: results of the OVERCOME (Japan) Study. Adv Ther. 2022;39:5176\u201390.","journal-title":"Adv Ther"},{"key":"663_CR8","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/WNO.0000000000000837","volume":"39","author":"KB Digre","year":"2019","unstructured":"Digre KB. What\u2019s new in the treatment of migraine? J Neuroophthalmol. 2019;39:352\u20139.","journal-title":"J Neuroophthalmol"},{"key":"663_CR9","unstructured":"Japanese Society of Neurology JHS, Japanese Society of Neurological Therapeautics. The Clinical Practice Guideline for Headache Disorders 2021 https:\/\/www.jhsnet.net\/pdf\/guideline_2021.pdf. Accessed 2024 July 12."},{"key":"663_CR10","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/d41573-023-00182-x","volume":"23","author":"K Chaudhari","year":"2024","unstructured":"Chaudhari K, Syed BA. The pipeline and market for migraine drugs. Nat Rev Drug Discov. 2024;23:246\u20137.","journal-title":"Nat Rev Drug Discov"},{"key":"663_CR11","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1503\/cmaj.211969","volume":"195","author":"V Tzankova","year":"2023","unstructured":"Tzankova V, Becker WJ, Chan TLH. Diagnosis and acute management of migraine. CMAJ. 2023;195:E153\u20138.","journal-title":"CMAJ"},{"key":"663_CR12","doi-asserted-by":"publisher","first-page":"9919773","DOI":"10.1155\/2021\/9919773","volume":"2021","author":"X Xu","year":"2021","unstructured":"Xu X, Ji Q, Shen M. Patient preferences and values in decision making for migraines: a systematic literature review. Pain Res Manage. 2021;2021:9919773.","journal-title":"Pain Res Manage"},{"key":"663_CR13","unstructured":"The American Headache Society. Acute migraine treatment. https:\/\/americanheadachesociety.org\/wp-content\/uploads\/2018\/05\/NAP_for_Web_-_Acute_Treatment_of_Migraine-1.pdf. Accessed 2024 July 12."},{"key":"663_CR14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.drudis.2019.05.001","volume":"24","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, Whichello C, Levitan B, et al. Methods for exploring and eliciting patient preferences in the medical product lifecycle: a literature review. Drug Discovery Today. 2019;24:1324\u201331.","journal-title":"Drug Discovery Today"},{"key":"663_CR15","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10488-010-0314-z","volume":"38","author":"LA Palinkas","year":"2011","unstructured":"Palinkas LA, Aarons GA, Horwitz S, et al. Mixed method designs in implementation research. Adm Policy Ment Health. 2011;38:44\u201353.","journal-title":"Adm Policy Ment Health"},{"key":"663_CR16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40120-023-00453-0","volume":"12","author":"J Seo","year":"2023","unstructured":"Seo J, Tervonen T, Ueda K, et al. Discrete choice experiment to understand Japanese patients\u2019 and physicians\u2019 preferences for preventive treatments for migraine. Neurol Ther. 2023;12:651\u201368.","journal-title":"Neurol Ther"},{"key":"663_CR17","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1111\/head.14476","volume":"63","author":"TJ Schwedt","year":"2023","unstructured":"Schwedt TJ, Martin A, Kymes S, et al. Patient preferences for attributes of injected or infused preventive migraine medications: findings from a discrete choice experiment. Headache. 2023;63:484\u201393.","journal-title":"Headache"},{"key":"663_CR18","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/head.14386","volume":"62","author":"LT Hubig","year":"2022","unstructured":"Hubig LT, Smith T, Chua GN, et al. A stated preference survey to explore patient preferences for novel preventive migraine treatments. Headache. 2022;62:1187\u201397.","journal-title":"Headache"},{"key":"663_CR19","doi-asserted-by":"publisher","first-page":"4916","DOI":"10.3390\/ijerph18094916","volume":"18","author":"A Torbica","year":"2021","unstructured":"Torbica A, Rognoni C, Tarricone R. Investigating patients\u2019 preferences to inform drug development decisions: novel insights from a discrete choice experiment in migraine. Int J Environ Res Public Health. 2021;18:4916.","journal-title":"Int J Environ Res Public Health"},{"key":"663_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1111\/head.13498","volume":"59","author":"C Mansfield","year":"2019","unstructured":"Mansfield C, Gebben DJ, Sutphin J, et al. Patient preferences for preventive migraine treatments: a discrete-choice experiment. Headache. 2019;59:715\u201326.","journal-title":"Headache"},{"key":"663_CR21","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s10194-017-0813-3","volume":"18","author":"DD Mitsikostas","year":"2017","unstructured":"Mitsikostas DD, Belesioti I, Arvaniti C, et al. Patients\u2019 preferences for headache acute and preventive treatment. J Headache Pain. 2017;18:102.","journal-title":"J Headache Pain"},{"key":"663_CR22","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, et al. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 2-assessing respondent understanding. Value Health. 2011;14:978\u201388.","journal-title":"Value Health"},{"key":"663_CR23","unstructured":"Qualtrics. Conjoint analysis white paper. https:\/\/www.qualtrics.com\/support\/conjoint-project\/getting-started-conjoints\/getting-started-choice-based\/conjoint-analysis-white-paper\/. Accessed 2024 July 12."},{"key":"663_CR24","unstructured":"Rakuten. https:\/\/insight.rakuten.com. Accessed 2024 July 12."},{"key":"663_CR25","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonz\u00e1lez JM, Groothuis-Oudshoorn CG, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR conjoint analysis good research practices task force. Value Health. 2016;19:300\u201315.","journal-title":"Value Health"},{"key":"663_CR26","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098614522683","volume":"5","author":"ES Kristoffersen","year":"2014","unstructured":"Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;5:87\u201399.","journal-title":"Ther Adv Drug Saf"},{"key":"663_CR27","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1111\/head.14154","volume":"61","author":"R Ishii","year":"2021","unstructured":"Ishii R, Schwedt TJ, Dumkrieger G, et al. Chronic versus episodic migraine: the 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency. Headache. 2021;61:992\u20131003.","journal-title":"Headache"},{"key":"663_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s40120-021-00305-9","volume":"11","author":"Y Matsumori","year":"2022","unstructured":"Matsumori Y, Ueda K, Komori M, et al. Burden of migraine in Japan: results of the observational survey of the epidemiology, treatment, and care of migraine (OVERCOME [Japan]) study. Neurol Ther. 2022;11:205\u201322.","journal-title":"Neurol Ther"},{"key":"663_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-024-01722-5","volume":"25","author":"T Takizawa","year":"2024","unstructured":"Takizawa T, Kitano T, Iijima M, Togo K, Yonemoto N. Treatment patterns and characteristics of patients with migraine: results from a retrospective database study in Japan. J Headache Pain. 2024;25:19.","journal-title":"J Headache Pain"},{"key":"663_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A. Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American Headache Society position statement update. Headache. 2024;64:333\u201341.","journal-title":"Headache"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00663-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-024-00663-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-024-00663-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T12:26:27Z","timestamp":1730895987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-024-00663-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["663"],"URL":"https:\/\/doi.org\/10.1007\/s40120-024-00663-0","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Takao Takeshima has been on the speakers\u2019 bureau for Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd., and has received research funding\/collaborative research expenses from AbbVie GK., Amgen K.K., Eli Lilly Japan K.K., Eisai Co., Ltd., Lundbeck Japan K.K., and Pfizer Japan Inc. Takao Takeshima also acted as an advisor to Hedgehog MedTech, Inc., Sawai Pharmaceutical Co., Ltd., and TEIJIN Pharma Ltd. AY, Kazumasa Kamei, and Masahiro Iijima are full-time employees of Pfizer Japan Inc. and hold stock or stock options in Pfizer Inc. Yukie Michelle Lloyd was an employee of IQVIA Japan G.K. at the time this study was conducted. Louis Patrick Watanabe and Akiho Terasawa are full-time employees of IQVIA Japan G.K. Josh Coulter and Brett Hauber are full-time employees of and hold stock or stock options in Pfizer Inc. Lucy Abraham is full-time employee of Pfizer R&D UK Ltd. and hold stock or stock options in Pfizer Inc. IQVIA Japan G.K. was compensated for their operational, research, and writing services.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in accordance with legal and regulatory requirements in Japan, and in accordance with the Helsinki Declaration of 1964 and its later amendments. An electronic informed consent was obtained on the questionnaire prior to participants entering the survey where the nature, purpose, and duration of the study were explained to each participant. Each participant was informed that they could withdraw from the study at any time and for any reason. The final protocol, any amendments, and informed consent documentation were reviewed and approved by the Shiba Palace Clinic Ethics Review Committee SOUKEN for this study on June 29, 2023 (No. 152411_rn-35258).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}